Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of localized (clinical American Joint Committee on Cancer \[AJCC\] stage Ta-T4N0M0) low- and high-grade UC of the renal pelvis and/or ureter~* Plan to undergo RNU~* Creatinine \< 2.2 mg/dL (194 mmol/L)~* Hemoglobin \> 9 g/dL~* White blood cell count \>= 3000/uL~* Platelet count \> 75,000/uL and \< 500,000/uL~* Serum bilirubin levels below 2 times the institution's upper limits of normal~* Alkaline phosphatase levels below 2 times the institution's upper limits of normal~* Aspartate aminotransferase levels below 2 times the institution's upper limits of normal~* Alanine aminotransferase levels below 2 times the institution's upper limits of normal~* Eastern Cooperative Oncology Group (ECOG) performance status score 0 - 2~* Suitable candidate for surgery at the discretion of the investigator~* Patient must be capable of giving appropriate approved informed consent or have an appropriate representative available to do~* Patient with a prior malignancy allowed if adequately treated \> 3 years ago with no current evidence of disease~* Women of childbearing potential (WOCBP) must have a negative pregnancy urine test within 28 days of registration, and be using an adequate method of contraception to avoid pregnancy prior to and for at least 6 months after gemcitabine instillation to minimize the risk of pregnancy~* Male patient who has a partner that is a WOCBP must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) and should avoid conceiving children prior to and for 6 months following gemcitabine instillation~Exclusion Criteria:~* Pure non-urothelial histology; urothelial carcinoma with differentiation allowed~* Evidence of nodal or distant metastases; enlarged retroperitoneal lymph nodes \> 2 cm or histologically positive lymph nodes~* History of UC of the bladder within 12 months preceding RNU, or receipt of intravesical therapy within 6 months~* History of or current prostatic urethral, urethral, or contralateral upper tract UC~* Planned radical cystectomy at time of RNU~* Symptomatic urinary tract infection of bacterial cystitis (once satisfactorily treated, patients can enter the study)~* Patient with any current malignancy except for basal or squamous cell skin cancers, noninvasive cancer of the cervix, or any other cancer deemed to be of low-risk for progression or patient morbidity during the trial period (i.e. Gleason 6 prostate cancer, renal mass \< 3 cm)~* Women who are pregnant or breastfeeding~* Prisoners or subjects who are involuntarily incarcerated~* Inability for adequate follow-up, including concerns for patient compliance or geographic proximity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prevention (gemcitabine hydrochloride) (Type: EXPERIMENTAL): Patients receive gemcitabine hydrochloride intravesically for at least 1 hour at the time of RNU.

Based on this trial design, predict the completion outcome and termination type (if applicable).